CC312
Phase 1Biologic
CC312 is one of 120 biologic programs targeting Autoimmune Disease. It is currently in Phase 1.
3
Indications
4
Total Trials
4
Active Trials
119
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
131 competitors in Safety and Efficacy
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Actemra
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Humira
RRanbaxy Laboratories Limited
Phase 3
Empaveli
Apellis PharmaceuticalsPhase 3
CAB LA
GSKPhase 3
Yervoy
Bristol-Myers SquibbPhase 2
B/F/TAF
GileadPhase 3
Eloxatin
TevaPhase 2
Nuzyra
PParatek Pharmaceuticals Inc
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Autoimmune Disease2 trials
Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CC312. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCytoCares Inc